Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite Complete Remission (cCR) (3 CR, 1CRh), all 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care;All cCR patients maintaining responses, from 4+ to 8+ months ongoing Ongoing enrollment in Phase 1 SENTI-202 study to confirm the preliminary recommended Phase 2 do ...

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Dune Acquisition Corporation II (the “Company”) announced today the pricing of its initial public offering of 12,500,000 units at a price of $10.00 per unit. The units will be listed on The Nasdaq Global Market (the “Nasdaq”) and trade under the ticker symbol “IPODU” beginning on May 7, 2025. Each unit consists of one Class A ordinary share and three-quarters of one redeemable warrant, with each whole warrant exercisable to purchase one Class A ordinary share at a ...

BETHESDA, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Host Hotels & Resorts, Inc. (NASDAQ: HST) (the “Company”), the nation’s largest lodging real estate investment trust, today announced that Host Hotels & Resorts, L.P. ("Host L.P."), for whom the Company acts as sole general partner, has priced its offering (the "Offering") of $500 million aggregate principal amount of 5.700% Senior Notes due 2032 (the "Notes"). The Notes are Host L.P.’s senior unsecured obligations. The Offering is expected to close on May 20, ...

THE WOODLANDS, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on Tuesday, May 20, at 9:30 a.m. ET. The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/. About Lexicon Pharmaceu ...

HAMPTON, N.H., May 06, 2025 (GLOBE NEWSWIRE) -- Unitil Corporation (NYSE: UTL) (unitil.com) today announced that it has entered into a definitive agreement to acquire Aquarion Water Company of Massachusetts Inc., Aquarion Water Company of New Hampshire, Inc., and Abenaki Water Co., Inc. (the “Aquarion Companies”) from the Aquarion Water Authority (“AWA”) for $100.0 million including the assumption of approximately $30.0 million of debt, subject to certain closing conditions, customary purchase price adjustm ...

ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction TodayACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that ACELYRIN stockholders vote “FOR” ...

AUSTIN, Texas, May 06, 2025 (GLOBE NEWSWIRE) -- Asure Software, Inc. (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management (“HCM”) software solutions, is scheduled to participate at the following financial conferences during May and June 2025: 20th Annual Needham Technology, Media and Consumer ConferenceDate: Tuesday, May 13, 2025Format: In Person 1x1 MeetingsLocation: New York, NY 22nd Annual Craig Hallum ConferenceDate: Wednesday, May 28, 2025Format: In Person 1x1 MeetingsLocation: Mi ...

VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTCQX: ATCMF) announces its operating results for the three months ended March 31, 2025 from its El Roble mine. Production for the quarter totaled 2.23 million pounds of copper and 1,553 ounces of gold in concentrates, a decrease of 33% for copper and 28% for gold, respectively, over the same period in 2024. “The El Roble mine performed below schedule this quarter as the transition ...

NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en ...

Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 04/30/2025 136,948,872 Total gross of voting rights: 136,948,872 Total net* of voting rights: 136,762,549 * Net total = total number of voting rights attached to shares – shares ...